NYSE:NNVC NanoViricides (NNVC) Stock Price, News & Analysis → Shocking $16T Elon Musk Crypto Leak (From Crypto 101 Media) (Ad) Free NNVC Stock Alerts $2.12 +0.05 (+2.42%) (As of 04:10 PM ET) Add Compare Share Share Today's Range$2.06▼$2.1550-Day Range$1.10▼$2.2552-Week Range$1.00▼$2.29Volume180,842 shsAverage Volume82,678 shsMarket Capitalization$25.04 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainSEC FilingsSocial Media Ad Paradigm PressDems have chosen Biden replacement?On November 16, 2023… Joe Biden accidentally revealed the name of the candidate… Who will replace him in the 2024 presidential election.See who it is HERE. About NanoViricides Stock (NYSE:NNVC)NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Read More NNVC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NNVC Stock News HeadlinesMay 20 at 8:47 AM | finanznachrichten.deNanoViricides, Inc.: Lethally RSV Infected Animals Orally Treated with NV-387 Showed Normal Lung Histology, Indicating Potential CureMay 20 at 8:16 AM | proactiveinvestors.comNanoViricides reports strong antiviral activity of NV-387 against RSVMay 19 at 9:15 AM | finance.yahoo.comNanoViricides, Inc. (NNVC) Stock Price, News, Quote & History - Yahoo FinanceMay 17 at 3:40 AM | americanbankingnews.comStockNews.com Initiates Coverage on NanoViricides (NYSE:NNVC)May 14, 2024 | proactiveinvestors.comNanoViricides unveils new data showing lead drug asset's strong activity against RSVMay 14, 2024 | finance.yahoo.comA Novel Broad-Spectrum Antiviral with Activity Against RSVMay 13, 2024 | proactiveinvestors.comNanoViricides CEO discusses NV-387's broad-spectrum antiviral potentialMay 10, 2024 | proactiveinvestors.comNanoViricides to showcase lead drug asset's progress at EF Hutton Annual Global ConferenceMay 10, 2024 | finanznachrichten.deNanoViricides, Inc.: NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York CityMay 8, 2024 | proactiveinvestors.comNanoViricides says lead asset shows antiviral activity against Smallpox and MpoxMay 8, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Smallpox/MpoxMay 8, 2024 | finance.yahoo.comNanoViricides, Inc. (NNVC)May 6, 2024 | ca.investing.comNanoViricides drug asset shows ‘superior antiviral effects’ against Influenza AMay 6, 2024 | msn.comNanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare moversMay 6, 2024 | proactiveinvestors.comNanoViricides drug asset shows ‘superior antiviral effects' against Influenza AMay 6, 2024 | finanznachrichten.deNanoViricides, Inc.: A Novel Broad-Spectrum Antiviral with Activity Against Influenza AApril 30, 2024 | proactiveinvestors.comNanoViricides completes Phase 1 trial of lead asset NV-387February 26, 2024 | benzinga.comNanoviricides Stock (AMEX:NNVC) Earnings Dates and Earning CallsFebruary 15, 2024 | proactiveinvestors.comNanoViricides boosts liquidity measures and manufacturing capacity to support clinical trialsFebruary 15, 2024 | finance.yahoo.comNanoViricides Has Filed its Quarterly Report - NV-387 Clinical Trial Healthy Subjects Part Successfully Completed, COVID Patient Treatment on the HorizonFebruary 1, 2024 | benzinga.comA New COVID-19 Variant Is Rapidly Spreading Around The Globe, Other Pandemic Threats Exist – What Are The Choices For Treatment?February 1, 2024 | finance.yahoo.comClinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as AntibioticsJanuary 29, 2024 | proactiveinvestors.comNanoViricides successfully concludes first-in-human studyJanuary 29, 2024 | proactiveinvestors.comNanoViricides makes progress as it completes dosing in Phase 1a COVID studyJanuary 29, 2024 | finance.yahoo.comSafety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the NanoViricides Ultra-Broad-Spectrum Antiviral Drug NV-CoV-2 with No Adverse Events FoundSee More Headlines Company Calendar Last Earnings5/15/2024Today5/20/2024Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNYSE:NNVC CUSIPN/A CIK1379006 Webwww.nanoviricides.com Phone(203) 937-6137Fax203-859-5095Employees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,590,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-74.66% Return on Assets-66.51% Debt Debt-to-Equity RatioN/A Current Ratio4.32 Quick Ratio4.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.28 per share Price / Book1.66Miscellaneous Outstanding Shares11,810,000Free Float11,271,000Market Cap$25.16 million OptionableOptionable Beta0.70 Key ExecutivesDr. Anil R. Diwan Ph.D. (Age 65)Executive Chairman, President, CEO & Secretary Comp: $400kMs. Meeta R. Vyas B.S. (Age 65)M.B.A., SB, MBA, Chief Financial Officer Comp: $129.6kDr. Randall W. Barton Ph.D. (Age 77)Chief Scientific Officer Key CompetitorsAptorum GroupNASDAQ:APMUnity BiotechnologyNASDAQ:UBXAcasti PharmaNASDAQ:ACSTQilian International Holding GroupNASDAQ:QLITherapeuticsMDNASDAQ:TXMDView All Competitors NNVC Stock Analysis - Frequently Asked Questions How have NNVC shares performed in 2024? NanoViricides' stock was trading at $1.02 at the start of the year. Since then, NNVC shares have increased by 108.8% and is now trading at $2.13. View the best growth stocks for 2024 here. How were NanoViricides' earnings last quarter? NanoViricides, Inc. (NYSE:NNVC) issued its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.16) earnings per share for the quarter. When did NanoViricides' stock split? NanoViricides's stock reverse split on the morning of Tuesday, September 24th 2019. The 1-20 reverse split was announced on Thursday, September 12th 2019. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 23rd 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of NanoViricides? Shares of NNVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NNVC) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldDoes this make you sick?Allegiance GoldThis Apple-like Innovator is Revolutionizing HealthcareWall Street Star**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1! Huge AlertsWarren Buffett's "mystery stock"Stansberry ResearchThis Could be Your “Big Money” AI MomentInvestorPlaceDigitizing the $11T commodities sector with one tiny stockResource Stock Digest Adding Choose a watchlist: Watchlist My Default Watchlist Adding NanoViricides, Inc. You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.